journal article·2024-10-22

Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA

Soraia Fernandes, Miriam Quattrociocchi, Marco Cassani, Giulio Savazzi, Darryl Johnson, Giancarlo Forte, Frank Caruso, Francesca Cavalieri

ACS Nano· Volume 18· Issue 42
Publisher page

Abstract

T cells play a major role in immune defense against viral infections and diseases such as cancer. Accordingly, developing nanoparticle (NP) systems to effectively deliver therapeutics to T cells is of interest. However, NP-mediated delivery of drugs to T cells is challenging because of the nonphagocytic nature of T cells. To engage T cells and induce cellular internalization, NPs are typically decorated with specific receptor-targeting antibodies, often using laborious and costly procedures. Herein, we report that natural glycogen NPs (i.e., nanosugars) with different sizes (20–80 nm) and surface charges (neutral and positively charged) engage Jurkat T cells, undergo intracellular trafficking, and release encapsulated drug without the use of receptor-targeting antibodies. Specifically, glycogen–resveratrol constructs are employed to reactivate HIV-1 latently infected Jurkat T cells (J-Lat A2) and trigger proviral expression. Both neutral and positively charged glycogen NPs engage with J-Lat A2 cells. Large (84 ± 29 nm) and positively charged (23 ± 5 mV) NPs, denoted phytoglycogen-ethylenediamine (PG EDA ) NPs, readily associate with the cell membrane and are internalized (60%) in J-Lat A2 cells but remain confined in the endocytic vesicles, with moderate reactivation of latent HIV-1 (4.7 ± 0.5%). Conversely, small (21 ± 5 nm) and positively charged (10 ± 6 mV) NPs, bovine glycogen-EDA (BG EDA ) NPs, associate slowly with T cells but show nearly 100% internalization and efficient endosomal escape properties, resulting in 1.5-fold higher reactivation of latent HIV-1 in T cells. PG EDA NPs and BG EDA NPs are also internalized by primary human T cells (>90% cell association) and enable the transfection of mRNA, with BG EDA NPs showing a 2-fold higher transfection than PG EDA NPs. This work highlights the potential of BG EDA NPs for the effective intracellular delivery of small-molecule drugs and mRNA in T cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, The University of Melbourne, Parkville 3010, Victoria, Australia

International Clinical Research Centre, St. Anne Hospital, 656 91 Brno, Czech Republic

Materials Characterization and Fabrication Platform, Department of Chemical Engineering, The University of Melbourne, Parkville 3010, Victoria, Australia

School of Cardiovascular and Metabolic Medicine & Sciences, King’s College London, London SE5 9NU, U.K.

School of Science, RMIT University, Melbourne 3000, Victoria, Australia

Dipartimento di Scienze e Tecnologie Chimiche, Universita di Roma “Tor Vergata”, Via Della Ricerca Scientifica 1, 00133 Rome, Italy

Funding

British Heart Foundation · National Health and Medical Research Council · H2020 Marie Sklodowska-Curie Actions · Australian Research Council · RMIT University

References (45)

Show source-provided references
1. 10.1002/adma.20190462510.1002/adma.201904625 ↗
2. 10.1039/D4SM00261J10.1039/D4SM00261J ↗
3. 10.17219/pim/9999310.17219/pim/99993 ↗
4. 10.1002/mds3.1011110.1002/mds3.10111 ↗
5. 10.1038/srep4001110.1038/srep40011 ↗
6. 10.1016/j.carbpol.2021.11799910.1016/j.carbpol.2021.117999 ↗
7. 10.2174/092986732466617070514330810.2174/0929867324666170705143308 ↗
8. 10.1039/D3TB00478C10.1039/D3TB00478C ↗
9. 10.1038/s42004-023-00829-110.1038/s42004-023-00829-1 ↗
10. 10.1038/s41598-021-04427-w10.1038/s41598-021-04427-w ↗
11. 10.3389/fbioe.2022.99014510.3389/fbioe.2022.990145 ↗
12. 10.1016/j.jconrel.2021.01.03310.1016/j.jconrel.2021.01.033 ↗
13. 10.1038/s41598-019-47995-810.1038/s41598-019-47995-8 ↗
14. 10.1038/s41565-023-01381-810.1038/s41565-023-01381-8 ↗
15. 10.1038/s41428-019-0296-y10.1038/s41428-019-0296-y ↗
16. 10.1038/s41467-021-21071-010.1038/s41467-021-21071-0 ↗
17. 10.1016/j.foodhyd.2019.10544210.1016/j.foodhyd.2019.105442 ↗
18. 10.1016/j.foodchem.2016.10.06410.1016/j.foodchem.2016.10.064 ↗
19. 10.1016/j.foodres.2017.04.02110.1016/j.foodres.2017.04.021 ↗
20. 10.1021/acsami.0c0278510.1021/acsami.0c02785 ↗
21. 10.1016/j.apmt.2019.10052110.1016/j.apmt.2019.100521 ↗
22. 10.1021/acs.biomac.1c0136010.1021/acs.biomac.1c01360 ↗
23. 10.1016/j.biomaterials.2018.05.02410.1016/j.biomaterials.2018.05.024 ↗
24. 10.2147/IJN.S7518810.2147/IJN.S75188 ↗
25. 10.1021/acs.bioconjchem.5b0031310.1021/acs.bioconjchem.5b00313 ↗
26. 10.2147/IJN.S5191910.2147/IJN.S51919 ↗
27. 10.1002/adma.20221039210.1002/adma.202210392 ↗
28. 10.1039/D1NR08429A10.1039/D1NR08429A ↗
29. 10.1021/acsnano.8b0515110.1021/acsnano.8b05151 ↗
30. 10.1002/adfm.20231124010.1002/adfm.202311240 ↗
31. 10.1039/C8BM01262H10.1039/C8BM01262H ↗
32. 10.1021/acsnano.0c0951410.1021/acsnano.0c09514 ↗
33. 10.1186/s12977-016-0325-210.1186/s12977-016-0325-2 ↗
34. 10.1093/emboj/cdg18810.1093/emboj/cdg188 ↗
35. 10.1093/emboj/20.7.172610.1093/emboj/20.7.1726 ↗
36. Aggarwal B. B. · Anticancer Res. · 2004 · 24 · 2783
37. 10.1021/acs.jafc.7b0041810.1021/acs.jafc.7b00418 ↗
38. 10.1016/j.jconrel.2012.01.00710.1016/j.jconrel.2012.01.007 ↗
39. 10.1016/j.jconrel.2014.02.01110.1016/j.jconrel.2014.02.011 ↗
40. 10.1016/j.bioadv.2022.21308310.1016/j.bioadv.2022.213083 ↗
41. 10.3389/fmicb.2022.83683110.3389/fmicb.2022.836831 ↗
42. 10.1038/srep2629410.1038/srep26294 ↗
43. 10.1083/jcb.20211013710.1083/jcb.202110137 ↗
44. 10.1021/acs.nanolett.9b0424610.1021/acs.nanolett.9b04246 ↗
45. 10.1038/s41565-018-0246-410.1038/s41565-018-0246-4 ↗